PRTG Stock Overview
Portage Biotech Inc., a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Portage Biotech Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.24 |
| 52 Week High | US$4.40 |
| 52 Week Low | US$0.20 |
| Beta | 99.75 |
| 1 Month Change | -55.52% |
| 3 Month Change | -71.37% |
| 1 Year Change | -92.81% |
| 3 Year Change | -99.16% |
| 5 Year Change | n/a |
| Change since IPO | -99.28% |
Recent News & Updates
Shareholder Returns
| PRTG | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -11.4% | 0.4% | 1.0% |
| 1Y | -92.8% | 0.9% | 21.9% |
Return vs Industry: PRTG underperformed the US Biotechs industry which returned 0.9% over the past year.
Return vs Market: PRTG underperformed the US Market which returned 21.9% over the past year.
Price Volatility
| PRTG volatility | |
|---|---|
| PRTG Average Weekly Movement | 22.5% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: PRTG's share price has been volatile over the past 3 months.
Volatility Over Time: PRTG's weekly volatility has increased from 17% to 23% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 7 | Ian Walters | www.portagebiotech.com |
Portage Biotech Inc., a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline includes PORT-2 for treatment of refractory NSCLC, melanoma, and refractory melanoma that is in phase I and phase II clinical trials; PORT-3, for treatment of solid tumors, which is in phase I clinical trials; PORT-6, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ia clinical trials; PORT-7, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ib clinical trials; PORT-1, an intratumoral amphiphilic solutions for treatment of advanced soft tissue sarcoma, which is in phase 3 clinical trials; PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; and PORT-5, a VLP-STING to treat of solid tumors that is in preclinical trials. The company is based in Tortola, British Virgin Islands.
Portage Biotech Inc. Fundamentals Summary
| PRTG fundamental statistics | |
|---|---|
| Market cap | US$4.75m |
| Earnings (TTM) | -US$144.90m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs PRTG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PRTG income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$144.90m |
| Earnings | -US$144.90m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -7.32 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did PRTG perform over the long term?
See historical performance and comparison